BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
Earnings
BioXcel Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q1 FY2026
–
EPS, Q1 FY2026
-$0.54
-$1.50 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of BioXcel Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026before the open | – | – | -$0.54 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 27, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | $98.00K | -54.2% | -$2.18 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | $120.00K | -89.1% | -$2.45 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | – | – | -$1.50 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025during market hours | – | – | -$3.57 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | $214.00K | – | -$0.32 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $1.10M | – | -$0.21 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 12, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 27, 2020during market hours | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 12, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Feb 19, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
BioXcel Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When BioXcel Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases BioXcel Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Update
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Update
See a number that looks wrong?